Search the Newsreel

Eupraxia Pharmaceuticals Stock Falls 8.75% as Clinical-Stage Volatility Tests Investor Confidence Despite Pipeline Potential

Eupraxia Pharmaceuticals Inc. (TSX:EPRX) stock declined 8.75% due to clinical-stage volatility, despite the potential of its proprietary DiffuSphere drug-delivery technology. The company's investment thesis focuses on improving existing active ingredients through controlled drug delivery, with a key development area in eosinophilic esophagitis using EP-104GI. …

What's Going On With Eupraxia Pharmaceuticals Inc Stock Wednesday?

EUPRAXIA PHARMACEUTICALS INC. SEC Filing (Aug 25, 2026)

This article reports on an SEC Filing (Form EFFECT) by EUPRAXIA PHARMACEUTICALS INC. (EPRX) that was accepted on August 25, 2026, with an effectiveness date of August 24, 2026. The filing has a neutral impact and sentiment according to AI analysis. The article also …

Eupraxia Pharmaceuticals Inc. (TSX:EPRX) Gains Investor Momentum as Clinical Progress and Pipeline Advancement Strengthen Biotechnology Outlook

Eupraxia Pharmaceuticals Independent Director Acquires 1.4% More Stock

Eupraxia Pharmaceuticals Inc. (TSE:EPRX) Independent Director John Montalbano recently purchased CA$207k worth of stock at CA$9.42 per share, increasing his holding by 1.4%. This follows a larger purchase by Independent Director Joseph Freedman last year for CA$2.7m at CA$9.59 per share, indicating insider confidence …

Eupraxia Pharmaceuticals Stock Falls 4.12% as Investors Weigh Clinical Progress Against Biotech Development and Financing Risk

Eupraxia Pharmaceuticals Inc. (TSX:EPRX) saw its stock decline by 4.12% due to investor reassessments of its clinical development, regulatory, and financing risks. The company's investment thesis centers on its DiffuSphere drug-delivery technology, aiming to provide controlled and targeted delivery of therapeutic compounds, especially for …

Eupraxia Pharmaceuticals Market Sentiment

This article provides an overview of market sentiment for Eupraxia Pharmaceuticals (EPRX), including analyst consensus, short interest, options flow, and insider activity. It highlights that 6 analysts have a "Buy" consensus with an average price target of $16, indicating a significant upside. The article …

Eupraxia (EPRX) Quarter in Focus: EPS Does Not Reach the Reported Estimate for This Review; Post-Report: Shares Fall 2.85% in the Available Record - Earnings Beat Alert

Eupraxia (Nasdaq: EPRX) lines up $300M in securities offerings

Eupraxia Pharmaceuticals Inc. (EPRX) has filed an amended Form F-10 shelf prospectus to register up to $300 million in various securities, including common and preferred shares, debt, warrants, subscription receipts, and units. This filing provides a flexible framework for future capital raises over a …

Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients

Eupraxia Pharmaceuticals Inc. announced positive symptom response data from its Phase 1b/2a RESOLVE trial for EP-104GI in Eosinophilic Esophagitis (EoE) patients. The analysis, which includes new data on odynophagia (painful swallowing), showed significant reductions in moderate to severe odynophagia and dysphagia (difficulty swallowing) lasting …

Eupraxia Pharmaceuticals (EPRX) Edges Higher to $6.72 as Biotech Sector Holds Steady - Equal Weight ETF

Eupraxia Pharmaceuticals (EPRX) Holds Gains as Shares Trade Near $6.72 - MFI Overbought

Eupraxia Pharmaceuticals (EPRX) Advances 0.75% as Price Approaches Key Resistance - Post-Earnings Moves

H.C. Wainwright Maintains Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating, Maintains Target Price $11

H.C. Wainwright has reiterated its Buy rating for Eupraxia Pharmaceuticals (EPRX.US) and maintained its target price at $11. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.

Eupraxia Pharmaceuticals (EPRX) holders report around 4–5% stakes in 13G/A

An amended Schedule 13G filing for Eupraxia Pharmaceuticals (EPRX) reveals that Manchester Management Company, LLC, Manchester Management PR, LLC, Manchester Explorer, L.P., James E. Besser, and Morgan C. Frank each report beneficial ownership of common shares ranging from approximately 4.1% to 4.5% of the …

Eupraxia reports symptom improvements in EoE trial analysis

Eupraxia Pharmaceuticals Inc. announced positive results from an analysis of its RESOLVE study, showing significant symptom improvements in eosinophilic esophagitis (EoE) patients treated with EP-104GI. The analysis revealed a substantial decrease in moderate to severe odynophagia and dysphagia, with severe symptoms dropping to zero …

Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia in Eosinophilic Esophagitis Patients

Eupraxia Pharmaceuticals announced positive symptom response data from its Phase 1b/2a RESOLVE trial for EP-104GI in Eosinophilic Esophagitis (EoE) patients. The analysis showed significant reductions in moderate to severe odynophagia (pain swallowing) and dysphagia (difficulty swallowing) lasting up to 52 weeks post-treatment, with no …

Eupraxia Pharmaceuticals (EPRX) shows durable EoE symptom relief in RESOLVE trial

Eupraxia Pharmaceuticals Inc (TSX:EPRX) Shares Decline as Clinical Development Risks and Biotechnology Market Volatility Pressure Sentiment

Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results

Eupraxia Pharmaceuticals announced its Q2 2026 financial results, reporting a net loss of $14.5 million, up from $8.7 million in Q2 2025. The company highlighted progress with its EP-104GI treatment for Eosinophilic Esophagitis (EoE), including positive Phase 1b/2a RESOLVE trial data and strengthening of …

Eupraxia Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Eupraxia Pharmaceuticals announced its Q2 2026 financial results, reporting a net loss of $14.5 million, up from $8.7 million in Q2 2025. The company highlighted progress with its EP-104GI treatment for Eosinophilic Esophagitis (EoE), including positive Phase 1b/2a RESOLVE trial data and strengthening of …

EPRX Stock Price and Chart — TSX:EPRX

This article provides a detailed overview of Eupraxia Pharmaceuticals, Inc. (EPRX) stock on the Toronto Stock Exchange, including its current price, historical performance, key financial statistics, and analyst ratings. It highlights the company's focus on drug delivery technology for conditions like arthritis and chronic …

Eupraxia Q2 EPS beats estimate despite wider net loss

Eupraxia Pharmaceuticals Inc. reported Q2 2026 EPS of $(0.23), surpassing analyst estimates of $(0.25) despite a wider net loss of $14.5 million, primarily due to increased R&D spending for its lead EoE asset, EP-104GI. The company maintains strong liquidity with $133.6 million in cash …

Eupraxia Pharmaceuticals (NASDAQ:EPRX) Issues Earnings Results

Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported a quarterly loss of $0.23 per share, surpassing analyst estimates by $0.02. Shares saw a modest increase of 0.6% to $6.70, and the company maintains strong financial liquidity. Analyst sentiment for EPRX is mixed but generally positive, with a "Moderate …

Eupraxia Pharmaceuticals (NASDAQ: EPRX) widens loss to $27.1M while raising $58.6M

Eupraxia Pharmaceuticals reported a widened net loss of $27.1 million for the six months ended June 30, 2026, primarily due to increased research and development and general and administrative expenses. Despite the larger loss, the company significantly boosted its liquidity by raising $58.6 million …

Wall Street Analysts See a 145.35% Upside in Eupraxia Pharmaceuticals Inc. (EPRX): Can the Stock Really Move This High?

Will Eupraxia Pharmaceuticals Inc (EPRX) Beat Earnings Estimates in Its Next Report?

Eupraxia Pharmaceuticals Inc (EPRX) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Eupraxia Pharmaceuticals Inc (EPRX), highlighting analyst ratings, target prices, and historical/projected EPS and revenue growth. Nine analysts currently rate EPRX as a "Buy" with a target price of USD 16.444, suggesting a 146.91% upside. The article also …

Eupraxia Pharmaceuticals Inc (EPRX) Stock News Today

This article provides current stock information for Eupraxia Pharmaceuticals Inc (EPRX), showing its stock price, market capitalization, and a brief overview of available financial data sections on the TradingKey platform. It indicates that more news regarding EPRX is expected soon. The content primarily serves …

Eupraxia Pharmaceuticals (NASDAQ: EPRX) sets up US$300M mixed securities shelf

Eupraxia Pharmaceuticals Inc. has filed a short form base shelf prospectus and accompanying Form F-10 to register up to US$300,000,000 in mixed securities, including common shares, preferred shares, debt securities, warrants, subscription receipts, and units. These securities may be offered over a 25-month period …

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Given Consensus Rating of "Moderate Buy" by Brokerages

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) has received a "Moderate Buy" consensus rating from brokerages, with an average 12-month price target of $18.00, significantly higher than its current price of $6.40. Despite the positive analyst sentiment, the company remains unprofitable, reporting a quarterly loss of $0.23 …

Eupraxia Pharmaceuticals (EPRX) Consolidates Near $6.50 as Investors Await Clinical Milestones - Unusual Put Volume

Eupraxia Pharmaceuticals (EPRX) to Post Earnings on Tuesday